This article is a correction to:
Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium
Bangtao Yao
Fei Wang
Xiaogui Zhao
Bei Wang
Xiaoli Yue
Yuhua Ding
Gang Liu- 1Department of Ophthalmology, Nanjing Lishui District People’s Hospital, Lishui Branch of Southeast University Affifiliated Zhongda Hospital, Nanjing, China
- 2Department of Ophthalmology, Jiangsu Province Hospital, The First Affifiliated Hospital of Nanjing Medical University, Nanjing, China
- 3Department of Pathology, Nanjing Lishui District People’s Hospital, Lishui Branch of Southeast University Affifiliated Zhongda Hospital, Nanjing, China
A corrigendum on
Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium
by Yao, B., Wang, F., Zha,o X., Wang, B., Yue, X., Ding, Y., and Liu, G. (2021). Front. Pharmacol. 12:709251. doi: 10.3389/fphar.2021.709251
In the original article, there was a mistake in Table 3 as published. Some numbers were wrongly reported in the COX-2, r, and p-value columns. “Additionally, there were multiple errors in the Results section due to incorrectly reported or missing values, which have now been corrected or added into the article.” The corrected Table 3 appears below.
TABLE 3
TABLE 3. Correlations between levels of VEGF and COX-2 expression in primary pterygium patients.
A correction has been made to the Results section, sub-section VEGF:
“The VEGF expression levels in the pterygium are listed in Tables 1 and 2. In group 1, there were 6, 7, 19, and 6 samples with a TS of 0, 3, 4, and 5, respectively. Six (15.8%), 7 (18.4%), and 25 (65.8%) samples were classified as negative (-), weak positive (+), and moderate positive (++), respectively. No samples were classified as strong positive (+++). In group 2, there were 1, 7, 13, 11, and 4 samples with a TS of 2, 3, 4, 5, and 6, respectively. One sample had a TS of 7. Eight (21.6%), 24 (64.9%), and 5 (13.5%) samples were classified as weak positive (+), moderate positive (++), and strong positive (+++), respectively. No sample was classified as negative (-). In group 3, there were 1, 6, 9, 19, and 3 samples with a TS of 2, 3, 4, 5, and 6, respectively. Two samples had a TS of 7. Seven (17.5%), 28 (70.0%), and 5 (12.5%) samples were classified as weak positive (+), moderate positive (++), and strong positive (+++), respectively. No sample was classified as negative (-) (Figures 1B,E,H) (Tables 1, 2).”
A correction has been made to the Results section, sub-section COX-2:
“The COX-2 expression levels in pterygium studied are listed in Tables 1, 2. In group 1, there were 3, 5, 4, 10, 9, and 7 samples with a TS of 0, 1, 2, 3, 4, and 5, respectively. Eight (21.1%), 14 (36.8%), and 16 (42.1%) samples were classified as negative (-), weak positive (+), and moderate positive (++), respectively. No samples were classified as strong positive (+++). In group 2, there were 1, 5, 7, 8, 12, and 4 samples with a TS of 1, 2, 3, 4, 5, and 6, respectively. One (2.7%), 12 (32.4%), 20 (54.1%), and 4 (10.8%) samples were classified as negative (-), weak positive (+), moderate positive (++), and strong positive (+++). In group 3, there were 1, 3, 1, 23, 9, and 3 samples with a TS of 1, 2, 3, 4, 5, and 6, respectively. One (2.5%), 4 (10.0%), 32 (80.0%), and 3 (7.5%) samples were classified as negative (-), weak positive (+), moderate positive (++), and strong positive (+++), respectively (Figure 1) (Tables 1, 2).”
A correction has been made to the Results section, sub-section Correlations Between TS and VEGF and COX-2 Expression:
“There were significant correlations between the TS and expression of VEGF and COX-2 in pterygial vascular endothelial cells within groups 1, 2, and 3 (all P < 0.05, Spearman's coefficient of correlation), as shown in Figure 2 and Table 3, respectively.”
Lastly, a correction has been made to the Results section, sub-section Group Comparisons:
“There were no significant differences in age, sex, eye type, combined systemic diseases, duration of the disease, IOP, and BCVA among the three groups (all p > 0.05). The TS and expression levels of VEGF and COX-2 in pterygium tissues in group 1 were significantly lower than those in groups 2 and 3 (all p < 0.05). However, there were no significant differences in TS and expression levels of VEGF and COX-2 between groups 3 and 2 (all P > 0.05) (Tables 1, 2).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: 0.1% pranoprofen, vascular endothelial growth factor, cyclo-oxygen-ase-2, pterygium, nonsteroidal anti-inflammatory drug
Citation: Yao B, Wang F, Zhao X, Wang B, Yue X, Ding Y and Liu G (2021) Corrigendum: Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium. Front. Pharmacol. 12:743733. doi: 10.3389/fphar.2021.743733
Received: 19 July 2021; Accepted: 29 July 2021;
Published: 13 August 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Yao, Wang, Zhao, Wang, Yue, Ding and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bangtao Yao, yaobamtao_njmu@163.com; Gang Liu, lg1974329@126.com; Yuhua Ding, dingyuhua_njmu@163.com; Xiaoli Yue, chyuech2020@163.com